Introduction: Pharmacogenetics is the study of inherited genetic variations in pathways responsible for metabolism of drugs and their effects on the individual responses. Cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme involved in the metabolism of many drugs. The CYP2D6 gene is highly polymorphic and currently more than 100 allelic variants have been reported for it. The combination of different alleles yields different phenotypes such as: extensive metabolizer (EM), intermediate metabolizer (IM) and poor metabolizer (PM). The most important IM allele with reduced activity of the enzyme is CYP2D6*10. Variant CYP2D6*4 is the most important null allelic variant responsible for eliminating enzymatic activity and a poor metabolism (PM). Genotyping of these two alleles in the population for assessing the efficacy of drug is of particular importance. TaqMan® assays are widely utilized for genotyping CYP2D6 alleles, but due to the existence of two pseudogenes, CYP2D7 and CYP2D8, and highly polymorphic nature of the gene, assay design can be challenging.
